Form 4: IN8BIO, INC. Executive Receives Stock Options

IN8BIO, INC. Chief Financial Officer Patrick McCall was granted employee stock options for 56,250 shares of common stock.

Summary

• Patrick McCall, Chief Financial Officer of IN8BIO, INC., was granted employee stock options on May 9, 2026.
• The options are for 56,250 shares of common stock with an exercise price of $1.58 per share.
• These options vest in four equal installments of 25% on November 9, 2026, May 9, 2027, November 9, 2027, and May 9, 2028, contingent upon continued service.
• The options have an expiration date of May 9, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event (stock option grant) rather than a significant financial or strategic development for the company.

Positives

• Grant of stock options to a key executive, aligning their interests with shareholders.
• The vesting schedule over several years encourages long-term commitment from the CFO.
• The exercise price of $1.58 suggests the options are granted at or near the current market price, potentially offering upside if the stock price increases.

Negatives

• The filing does not provide details on the company's current financial performance or stock price, making it difficult to assess the immediate value of these options.
• The vesting is contingent on continued service, meaning the executive could forfeit unvested options if they leave the company.

Risks

• The value of the stock options is directly tied to the future performance of IN8BIO, INC.'s stock price, which is subject to market volatility and company-specific risks.
• If the company's stock price does not exceed the exercise price of $1.58, the options may not hold significant value.

Future Outlook

The stock options granted to Patrick McCall are exercisable starting from November 9, 2026, with full vesting by May 9, 2028, and expire on May 9, 2036. The value realized will depend on the company's stock performance.

Industry Context

StockSavvy.ai notes that the issuance of stock options to a Chief Financial Officer is a common practice in the biotechnology sector to attract and retain executive talent, aligning their compensation with the long-term success of the company, especially given the often volatile nature of early-stage biotech firms.

Stakeholder Impact

• Shareholders: The grant of options aligns executive interests with shareholder value creation, but also dilutes ownership slightly upon exercise.
• Employees: May signal a stable leadership team, but the direct impact is limited to the executive receiving the options.
• Management: Reinforces the compensation structure for key executives.

Next Steps

• Patrick McCall will continue to provide services to IN8BIO, INC. through the vesting dates to acquire the granted shares.
• The company's stock performance will determine the ultimate value and exercise of these options.

Key Dates

Keywords

IN8BIO, INC., INAB, Form 4, Stock Options, Executive Compensation, Patrick McCall, Chief Financial Officer, Beneficial Ownership, Securities Exchange Act